Table 2.

Characteristics of donors of lungs that underwent EVLP.

	Cause of death	Age	Smoking	CXR	Secretions	BAS	OTO	P/F	MV	CVP	WBC	Comorbidities	Vasopressors	CCA
1	Cerebrovascular	45	50	+	–	–	11	180	7	14	10.3	–	NA, DP	NO
2	Cerebrovascular	53	48	+	–	–	10	188	1	15	7.42	DB, LD, AH	NA, DP	NO
3	Postanoxic	63	10	–	+	S.Aureus	6	395	5	13	18.2	HT	NA, DB	YES
4	Cerebrovascular	59	0	+	+	–	10	280	1	13	16.5	–	NA, DP	NO
5	Cerebrovascular	48	10	–	++	P.Aerug	9	155	3	13	2.66	LD, AH	NA	NO
6	Cerebrovascular	60	56	+	++	K.Pn;K.Ox	14	258	3	8	14.3	AH	NA	NO
7	Cerebrovascular	38	54	+	+	H.Infl	11	283	2	13	12.7	–	NA, DP	YES
8	Cerebrovascular	59	0	+	++	–	12	158*	8	17	17.1	IHD, CS, AH	NA, DB	NO

Age, years; Smoking, smoking history (packs/year); CXR, chest X-ray: (–) clear, (+), abnormal; Secretions: (–) none, (+) minor, (++) moderate; BAS, bronchoaspirate; OTO, Oto score ¹²; P/F, PaO₂/FiO₂ ratio; MV, duration of mechanical ventilation (days); CVP, central venous pressure; WBC, white blood cells; CAA, cardio-circulatory arrest; DB, diabetes; AH, arterial hypertension; HT, hypothyroidism; LD, liver disease; IHD, ischemic heart disease; CS, cardiogenic shock; NA, noradrenaline; DP, dopamine; DB, dobutamine; L, levosimendan. S.Aureus, Staphylococcus aureus; P.Aerug, Pseudomonas Aeruginosa; K.Pn, Klebsiella pneumoniae; K.Ox, Klebsiella oxytoca; H.Inf, Haemofilus influenzae.

^*While on full veno-arterial Extracorporeal Membrane Oxygenation (ECMO) support for cardiogenic shock treatment.